Latest Stock Market News

The Nifty IT index closed 0.01 per cent down at 41311.15.

Manappuram Finance Ltd., incorporated in the year 1992, is a Mid Cap company (having a market cap of Rs 15022.52 Crore) operating in NBFC sector.

Despite a weak economic environment, Q3 FY25 showed strong recoveries across key sectors. Rural demand boosted automobile sales, BFSI revival aided IT growth, and oil, pharma, banking, consumer, and telecom sectors saw improved profitability. Market resilience and sectoral rebounds drove better-than-expected financial performance.

Rising operational costs, weak demand, and margin pressures impacted multiple sectors in Q3 FY25. Automobiles, IT, oil & gas, pharma, banking, and consumer industries faced challenges, with muted volume growth, weaker discretionary spending, and profitability constraints affecting overall performance.

Six Nifty200 large-cap stocks- Tata Power, Jio Financial, LIC, PNB, Hero MotoCorp, and DLF hit 52-week lows amid concerns over US tariffs. Year-to-date declines range from 8% to 28%.

Citi forecasts rapid expansion for Swiggy s quick commerce (QC) business, with dark store footprints expected to double again in 2025. The firm projects a 73% CAGR in gross order value (GOV) for Swiggy’s QC segment, reaching $26 billion by FY28. Meanwhile, Swiggy’s food delivery business is expected to grow at 18% CAGR, reaching $13 billion in the same period.

Mayuresh Joshi highlights European market resilience, benefiting Indian exporters in cement, steel, and textiles. Strong domestic plays include agrochemicals and hospitals, while consumer stocks like Nykaa and Honasa show recovery potential. Market trends favor selective sectoral growth.

The Indian rupee logged its biggest weekly rise against the dollar in seven months, lifted by the central bank s heavy intervention in the foreign exchange market and kept speculators betting against the currency at bay.

Stock Market Highlights: Indian benchmark indices extended their losses on Friday, with all 13 major sectors ending in the red, as investors worried about the impact of U.S. President Donald Trump s proposed reciprocal tariffs. Pharma stocks, heavily reliant on U.S. revenue, faced the sharpest declines.

Wherever there is overvaluation, you will continue to see a nervousness and clearly the broader end of the market is still quite expensive compared to largecaps or compared to even their own historical average valuations.